These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23418355)

  • 21. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
    Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
    Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.
    Pfeifer A; Eigenbrod S; Al-Khadra S; Hofmann A; Mitteregger G; Moser M; Bertsch U; Kretzschmar H
    J Clin Invest; 2006 Dec; 116(12):3204-10. PubMed ID: 17143329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation.
    Filesi I; Cardinale A; Mattei S; Biocca S
    J Neurochem; 2007 Jun; 101(6):1516-26. PubMed ID: 17542810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of an intracellular site of prion conversion.
    Marijanovic Z; Caputo A; Campana V; Zurzolo C
    PLoS Pathog; 2009 May; 5(5):e1000426. PubMed ID: 19424437
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of endoproteolytic α-cleavage and shedding of the prion protein in neurodegeneration.
    Altmeppen HC; Prox J; Puig B; Dohler F; Falker C; Krasemann S; Glatzel M
    FEBS J; 2013 Sep; 280(18):4338-47. PubMed ID: 23413979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prion protein amyloid: separation of scrapie infectivity from PrP polymers.
    Wille H; Baldwin MA; Cohen FE; DeArmond SJ; Prusiner SB
    Ciba Found Symp; 1996; 199():181-99; discussion 199-201. PubMed ID: 8915611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Folding and misfolding of the prion protein in the secretory pathway.
    Tatzelt J; Winklhofer KF
    Amyloid; 2004 Sep; 11(3):162-72. PubMed ID: 15523918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global analysis of protein degradation in prion infected cells.
    Hutti CR; Welle KA; Hryhorenko JR; Ghaemmaghami S
    Sci Rep; 2020 Jul; 10(1):10800. PubMed ID: 32612191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic aspects of prion diseases: an overview.
    Vranac T; Bresjanac M
    Curr Drug Targets; 2010 Oct; 11(10):1207-17. PubMed ID: 20840065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ubiquitin-specific protease 14 modulates degradation of cellular prion protein.
    Homma T; Ishibashi D; Nakagaki T; Fuse T; Mori T; Satoh K; Atarashi R; Nishida N
    Sci Rep; 2015 Jun; 5():11028. PubMed ID: 26061634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular and sub-cellular pathology of animal prion diseases: relationship between morphological changes, accumulation of abnormal prion protein and clinical disease.
    Jeffrey M; McGovern G; Sisó S; González L
    Acta Neuropathol; 2011 Jan; 121(1):113-34. PubMed ID: 20532540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
    Sasaki K; Minaki H; Iwaki T
    J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake.
    Wolf H; Graßmann A; Bester R; Hossinger A; Möhl C; Paulsen L; Groschup MH; Schätzl H; Vorberg I
    J Virol; 2015 Oct; 89(19):9853-64. PubMed ID: 26202247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FBXW7-Induced MTOR Degradation Forces Autophagy to Counteract Persistent Prion Infection.
    Xu Y; Tian C; Sun J; Zhang J; Ren K; Fan XY; Wang K; Wang H; Yan YE; Chen C; Shi Q; Dong XP
    Mol Neurobiol; 2016 Jan; 53(1):706-719. PubMed ID: 25579381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subcellular distribution of the prion protein in sickness and in health.
    Godsave SF; Peters PJ; Wille H
    Virus Res; 2015 Sep; 207():136-45. PubMed ID: 25683509
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.
    Perrier V; Solassol J; Crozet C; Frobert Y; Mourton-Gilles C; Grassi J; Lehmann S
    J Neurochem; 2004 Apr; 89(2):454-63. PubMed ID: 15056288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Styryl-based and tricyclic compounds as potential anti-prion agents.
    Chung E; Prelli F; Dealler S; Lee WS; Chang YT; Wisniewski T
    PLoS One; 2011; 6(9):e24844. PubMed ID: 21931860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles.
    Alais S; Simoes S; Baas D; Lehmann S; Raposo G; Darlix JL; Leblanc P
    Biol Cell; 2008 Oct; 100(10):603-15. PubMed ID: 18422484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequestration of free cholesterol in cell membranes by prions correlates with cytoplasmic phospholipase A2 activation.
    Bate C; Tayebi M; Williams A
    BMC Biol; 2008 Feb; 6():8. PubMed ID: 18269734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein.
    Homma T; Ishibashi D; Nakagaki T; Satoh K; Sano K; Atarashi R; Nishida N
    Sci Rep; 2014 Mar; 4():4504. PubMed ID: 24675871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.